Products

The patents cover combinations of polymers and granular materials and further expand Kuros' patent portfolio relating to its MagnetOs product.

The transitional pass-through payment reimburses outpatient centers and ASCs for incremental cost of AUGMENT in hindfoot and ankle fusion.

The limited market release of Tempest Allograft Bone Matrix marks Spine Wave's entry into the spinal biologics market.

The product expands Aziyo's regenerative medicine portfolio and leverages proprietary processing to protect and preserve native bone cells.

STIMULAN is the first calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft tissue.

BONESUPPORT's bone graft substitutes are based on the patented CERAMENT technology platform. Direct sales commence in July 2020.

Results show that elderly patients undergoing non-instrumented fusion achieve statistically significantly higher fusion rates with i-FACTOR vs. allograft.

The JTA-004 Phase III study is approved in five of seven territories. These are the first patients treated after resumption of clinical activities.

InGeneron announces favorable study results using regenerative autologous adipose-derived cells that are prepared with the Transpose® RT System for treatment of partial-thickness rotator cuff tears.

BBS-Bioactive Bone Substitutes' patent application protecting ARTEBONE® bone graft substitute has been accepted in the U.S.